Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Trial Profile

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Dasatinib (Primary) ; Erlotinib (Primary) ; Everolimus (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Acronyms BIOMEDE
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2015 Planned number of patients changed from 225 to 250 as reported by ClinicalTrials.gov record.
    • 24 Nov 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top